Abstract: The application disclosed a cell proliferation factor-Fwa267 polypeptide and the polynucleotide encoding the polypeptide and a process for producing the polypeptide by recombinant method, the antibody and antagonist against the polypeptide and a composition comprising Fwa267 polypeptide and its usage in the treatment of angiocardiopathy and cancer are also disclosed. The application further disclosed a diagnostic method by detecting the mutation in the nucleic acid sequence encoding Fwa 267 or the amount of Fwa267 in the sample or the changes of autoantibody of Fwa267 gene product. The cell proliferation factor of the present application is of human resource.

Abstract: The present invention relates to a polypeptide of the inflammatory inhibition factor Fwa116 and the polynucleotides encoding thereof. The present invention also relates to the method of producing polypeptide Fwa116 by recombinant technology and the antibody against it and an antagonist. The present invention also discloses pharmaceutical compositions containing the polypeptide Fwa116 and the use of the polypeptide in treating cardiovascular inflammatory arterosclerosis such as cerebral apoplexy, coronary heart disease, angina pectoris, myocardial infarction and controlling tumors. The present invention also provides the diagnosing and measuring method by detecting the mutation of nucleic acid sequence encoding Fwa116 or the content of the polypeptide Fwa116 and changes in levels of the auto-antibody of the gene product of Fwa116. The present inflammatory inhibition factor is human-derived.